1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Eribulin; Fulvestrant
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium.